Hydroxyethyl Starch 480/0.7 Pharma Grade API is a hydroxyethylated amylopectin derivative obtained by controlled alkaline etherification of waxy maize or potato starch with ethylene oxide. The model identification encodes two critical structural specifications: a nominal weight-average molecular weight of 480,000 Da and a molar substitution of 0.7 hydroxyethyl groups per anhydroglucose unit. The substituted polymer is cold-water-soluble and does not form firm gels on cooling in neutral aqueous media, in contrast to unmodified amylose-containing starch. The API is supplied as a white to off-white, free-flowing powder and is used in oral solid dosage forms as a soluble binder, while in injectable preparations it functions as a colloid-active polymer after dissolution, depyrogenation, and terminal sterilization. Pharmacopoeial control includes loss on drying by Ph. Eur. 2.2.32, residue on ignition by Ph. Eur. 2.2.35, bacterial endotoxins by Ph. Eur. 2.6.14, and elemental impurities by USP 232/233 under ICH Q3D.

Table 1: Typical specification targets for Hydroxyethyl Starch 480/0.7 Pharma Grade API.

What Limits Direct Aqueous Granulation Performance at 480/0.7?

In wet granulation, aqueous solutions of this grade develop higher extensional viscosity than povidone K30 or hydroxypropyl cellulose at equivalent solids. The molecular-weight fraction above 1,000,000 Da is primarily responsible for interparticulate bridge strength but also for delayed wetting of dry powders. Production-scale experience indicates that a binder solution of 3–8% w/w hydroxyethyl starch in purified water is generally suitable for lactose–microcrystalline cellulose blends, but the binder addition rate during high-shear granulation must be reduced as solution viscosity exceeds 150 mPa·s at 20 °C. A high-shear granulator operating at impeller tip speeds of 4–6 m/s and chopper speeds of 1,500–3,000 rpm can produce acceptable granule size distribution if the wet mass is not over-massed. Over-granulation produces dense, slow-disintegrating granules; disintegration time of the final tablet is evaluated according to Ph. Eur. 2.9.1 or USP 701. If final tablet hardness exceeds 80 N, the formulation may require a wicking disintegrant such as croscarmellose sodium at 2–5% w/w to maintain disintegration below 15 min.

Encapsulation with the 480/0.7 grade as a binder in wet-massed or roller-compacted granules requires moisture content to be brought below 4% w/w before filling. Residual moisture above this threshold increases tackiness on dosator pins and tamping pins during automatic capsule filling, particularly on machines operating above 60,000 capsules/h. The API particle-size distribution should have a D90 below 100 µm for uniform die filling; larger particles segregate in the feed frame and contribute to weight variation beyond 2% RSD. When the grade is used as a dry binder for direct compression, its plastic deformation behavior is insufficient at pressures below 150 MPa; a co-processed excipient or a harder filler such as dibasic calcium phosphate anhydrous is normally required. Tablet tensile strength can be evaluated by the diametral compression method described in USP 1217 or Ph. Eur. 2.9.8.

Injectable Formulation Constraints and Endotoxin Control

Parenteral use of Hydroxyethyl Starch 480/0.7 requires depyrogenation and aseptic downstream handling. The API is not sterile at release; terminal sterilization of the finished solution is performed by steam sterilization at 121 °C for 15 min or by autoclaving cycles validated to a sterility assurance level of 10⁻⁶ according to Ph. Eur. 5.1.1 and ISO 14937. The pH of the formulation should be adjusted to 5.0–7.0 before terminal sterilization because acidic pH accelerates hydrolytic cleavage of the α-1,4-glycosidic backbone. Hydroxyethyl substitution on the C2 and C6 positions inhibits amylase degradation, but steam sterilization can reduce the weight-average molecular weight by up to 15–25%; the finished-product molecular weight distribution is therefore controlled by size-exclusion chromatography with multi-angle light scattering. Endotoxin control is exercised at the API level using the Limulus amebocyte lysate method of Ph. Eur. 2.6.14 or USP 85, with a commonly applied API acceptance criterion of ≤0.25 EU/mg for parenteral-grade material. The formulated isotonic solution is typically 6% w/v in 0.9% sodium chloride. Published data for this specific configuration is limited beyond the approved prescribing information for finished hetastarch products. This grade is not interchangeable with HES 130/0.4 in volume replacement because the higher molar substitution and molecular weight impart longer intravascular persistence and greater plasma volume expansion per gram, but also alter renal handling and coagulation parameters. Avoid combination with strongly acidic buffers and high-energy heat cycles; oxidative chain scission lowers molecular weight and raises reducing end groups.

When Wet Granulation Is Replaced by Roller Compaction

Roller compaction of HES 480/0.7-containing formulations shifts the critical process parameter from binder solution viscosity to ribbon solid fraction and post-compaction granule friability. The material is not sufficiently compressible to serve as the sole binder when roller compaction is operated below 0.65 solid fraction; ribbons with lower density crumble into fines and increase the fraction below 125 µm. A suitable formulation includes microcrystalline cellulose at 20–40% w/w and magnesium stearate at 0.5–1.0% w/w; the stearate should be added pre-blend only after the starch component has been deagglomerated. Published data for this specific configuration is limited, so ribbon density and granule particle-size distribution should be characterized using USP 429 and Ph. Eur. 2.9.31. The dissolution rate of HES 480/0.7 tablets can be determined using USP 711 apparatus 2 at 50 rpm and 37 °C; because the polymer is fully water-soluble, dissolution is typically matrix-controlled rather than diffusion-limited, and release follows near zero-order kinetics when tablet porosity is below 0.15.

Comparative Differentiation against Lower-Molecular-Weight Hydroxyethyl Starches

The 480/0.7 grade occupies a different formulation and clinical position than HES 130/0.4 or HES 200/0.5. The higher molar substitution of 0.7 restricts enzymatic hydrolysis by α-amylase, so intramolecular persistence is longer than for a 0.4-substituted polymer at equivalent molecular weight. In solid dosage forms, this means the 480/0.7 grade can form stronger interparticulate bridges at lower binder concentrations but also requires more water to reduce viscosity to pumpable levels. The colloid osmotic pressure of a 6% solution of 480/0.7 is higher than that of a 6% solution of 130/0.4; however, the corresponding increased oncotically active fraction means dose reductions are usually required for patients with impaired renal function. From a compendial perspective, the grade is not automatically interchangeable with HES 130/0.4 or HES 200/0.5 monographs; each grade must be tested against the applicable monograph for identity, substitution pattern, molecular weight distribution, and bacterial endotoxins.

Table 2: Comparative profile of selected hydroxyethyl starch grades.